PRECIGEN, INC. Defined Contribution Plan, Cost
PRECIGEN, INC. (PGEN) reported Defined Contribution Plan, Cost of $505.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-25
- PRECIGEN, INC. defined contribution plan, cost for fiscal 2025 was $505.00K, a 21.10% increase from fiscal 2024.
- PRECIGEN, INC. defined contribution plan, cost for fiscal 2024 was $417.00K, a 134.27% increase from fiscal 2023.
- PRECIGEN, INC. defined contribution plan, cost for fiscal 2023 was $178.00K, a 68.44% decline from fiscal 2022.
- PRECIGEN, INC. defined contribution plan, cost for fiscal 2022 was $564.00K, a 45.36% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $505.00K 10-K · filed 2026-03-25 | |
| 2024-12-31 | $417.00K 10-K · filed 2026-03-25 | |
| 2023-12-31 | $178.00K 10-K · filed 2026-03-25 | |
| 2022-12-31 | $564.00K 10-K · filed 2025-03-19 | |
| 2021-12-31 | $388.00K 10-K · filed 2024-03-19 | $887.00K 10-K · filed 2022-03-01 |
| 2020-12-31 | $397.00K 10-K · filed 2023-03-06 | $873.00K 10-K · filed 2021-03-01 |
| 2019-12-31 | $1.19M 10-K · filed 2022-03-01 | $1.43M 10-K · filed 2020-03-02 |
| 2018-12-31 | $1.39M 10-K · filed 2021-03-01 | $2.49M 10-K · filed 2019-03-01 |
| 2017-12-31 | $1.54M 10-K · filed 2020-03-02 | $2.37M 10-K · filed 2018-03-01 |
| 2016-12-31 | $1.86M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $1.16M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $776.00K 10-K · filed 2017-03-01 | |
| 2013-12-31 | $598.00K 10-K · filed 2016-02-29 | |
| 2012-12-31 | $755.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $433.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |